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Xiao YangAbstract
Targeted mutagenesis based on homologous recombination has been a powerful tool for understanding the
mechanisms underlying development, normal physiology, and disease. A recent breakthrough in genome
engineering technology based on the class of RNA-guided endonucleases, such as clustered regularly interspaced
short palindromic repeats (CRISPR)-associated Cas9, is further revolutionizing biology and medical studies. The
simplicity of the CRISPR-Cas9 system has enabled its widespread applications in generating germline animal
models, somatic genome engineering, and functional genomic screening and in treating genetic and infectious
diseases. This technology will likely be used in all fields of biomedicine, ranging from basic research to human
gene therapy.
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In the post-genome era, further defining the biological
function of genome sequences and their transcripts in
development and disease is a huge challenge. Targeted
mutagenesis in whole animal is a powerful method to
elucidate gene function in a physiological setting. The
development of gene targeting, in which specific gene
modification can be introduced into the animal genome
through homologous recombination and embryonic
stem cell technology, has revolutionized biological and
biomedical studies [1]. Genetically modified animals,
especially gene knockout mice, have been valuable as
human disease models. The second generation of gene
targeting, conditional gene targeting based on site-
specific recombinases, primarily the Cre-LoxP system,
enables the creation of animals carrying targeted muta-
tions in specific cell types or in an inducible manner
[2]. A new generation of genome engineering technolo-
gies based on the class of RNA-guided endonucleases,
such as clustered regularly interspaced short palin-
dromic repeats (CRISPR)-associated Cas9, and their
rapid applications are now bringing a further revolution
in biology and medicine [3,4]. This review will focus onCorrespondence: yangx@bmi.ac.cn
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unless otherwise stated.the recent progress of the applications of CRISPR-
Cas9-mediated genome engineering.Review
CRISPR-Cas9 technology
The CRISPR-Cas9 technology is developed from type II
CRISPR-Cas systems, by which bacteria degrade targeted
nucleic acids [5,6]. CRISPRs are characterized features of
the genomes of most bacteriophage-resistant Bacteria
and Archaea. Cas9, a CRISPR-associated endonuclease
with putative nuclease and helicase domains, can be
localized to specific DNA loci and make double-strand
breaks under the guidance of the trans-activating
CRISPR RNA (tracrRNA):CRISPR RNA (crRNA) duplex
(Figure 1) [7-9]. tracrRNA has been shown to help RNA
to direct the maturation of crRNAs by host RNase III
and the CRISPR-associated Csn1 protein, protecting S.
pyogenes against prophage-derived DNA [9]. Further
studies have shown that the tracrRNA:crRNA duplex
directs the CRISPR-associated protein Cas9 from S.
thermophilus or S. pyogenes to use two distinct active
sites, RuvC and HNH, and cleave the two strands in the
target DNA, which is complementary to the crRNA
[10,11]. The dual tracrRNA:crRNA was further developed
as a single-guide RNA (sgRNA) for genome engineering
and contains the 5′ end 20-nucleotide sequence determin-
ing the DNA target site according to Watson-Crick basean Open Access article distributed under the terms of the Creative Commons
rg/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
Figure 1 The CRISPR-Cas system. The CRISPR-associated endonuclease Cas9 could target specific DNA loci and make double-strand breaks under
the guidance of the tracrRNAs:crRNAs duplex. The tracrRNA:crRNA duplex directs Cas9 to use two distinct active sites, RuvC and HNH, and cleave
the target DNA complementary to the crRNA, which has an adjacent protospacer-adjacent motif (PAM).
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Cas9 [10]. The sgRNA could direct CRISPR-Cas9 to any
target DNA sequence with an adjacent protospacer-
adjacent motif (PAM) by changing the guide RNA
sequences [12-14]. Expectedly, the CRISPR-Cas9 has been
shown to be an effective approach for genome editing in
human cells [15-17]. The simplicity of the CRISPR-Cas9
system has enabled widespread applications of this system
for efficient genome engineering in various species.
A major concern in the application of CRISPR-Cas9
technology is the targeting specificity of Cas9 nucleases.
A number of studies have shown that Cas9 could toler-
ate some mismatches between the guide RNA and its
complementary target DNA sequence, causing potential
off-site targeting [10,15,18]. Off-site targeting is largely
affected by the number, position, distribution of mis-
matches and Cas9 concentration, and may be a major
concern in CRISPR/Cas9-medicated genome engineering
[15,19-22]. Genome-wide Cas9 cutting specificity has been
studied by high-throughput Cas9-based chromatin im-
munoprecipitation sequencing (ChIP-seq) analysis [23-25],
and more unbiased experiments are required for elucidat-
ing the mechanisms of Cas9 binding and cleavage specifi-
city. Further optimizations using the double nicking
strategy and shorter sgRNAs have significantly reduced off-
target activity [26,27]. Several groups have provided tools
for designing highly active sgRNAs and minimizing off-site
targeting (http://tools.genome-engineering.org, http://zifit.
partners.org, and www.e-crisp.org) [28-32].
CRISPR-Cas9 in the generation of animal models
Gene targeting based on homologous recombination and
embryonic stem cells has been used as the typical ap-
proach for animal genome modification, which has
played indispensable roles in making a causal linkbetween genomic mutations and phenotypes during
development and in disease. However, gene targeting
has limited applications in some organisms due to
time-consuming procedures and the lack of available
embryonic stem cells. Many recent studies have shown
that CRISPR-Cas9 technology could be used for rap-
idly generating targeted genome modifications in the
germ lines of various model organisms [33-47], which
will significantly advance the functional genomics.
Microinjection of Cas9-encoding mRNA and customizable
sgRNA into one-cell stage zebrafish embryos is able to
efficiently modify the target genes in vivo in a simple,
rapid and scalable manner [33,34]. Co-injection of Cas9
mRNA and sgRNAs targeting different genes into
mouse zygotes generates mutant mice with biallelic
mutations, confirming that CRISPR/Cas-mediated gene
editing could be used for the simultaneous disruption
of multiple genes with high efficiency [35]. Gene
knockin mice carrying precise point mutations of two
genes can be obtained by co-injection of Cas9 mRNA/
sgRNAs together with mutant oligos [36]. The following
study demonstrates that reporter and conditional mutant
mice can also be generated in one step by co-injecting
mouse zygotes with Cas9 mRNA and different sgRNAs, as
well as DNA vectors of different sizes. Additionally, mice
with the predicted deletions have been generated using
sgRNAs targeting two separate sites in the gene [35].
Multiplexed activation of endogenous genes can be
achieved by injecting a two-component transcriptional
activator including a nuclease-dead Cas9 protein fused
with a transcriptional activation domain and sgRNAs
targeting gene promoters [37]. These previous studies
have demonstrated that CRISPR-Cas9 technology can
be used for efficient one-step generation of various so-
phisticated mutant mice, including mice carrying gene
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reporters at different loci. A recently established Cre-
dependent Cas9 knockin mouse may further facilitate the
generation of genetic modified mutant mice by simply
injecting sgRNA [38].
CRISPR-Cas9 technology has been used for efficient
genome engineering in many other model organisms, in-
cluding Drosophila [39,40], Caenorhabditis elegans [41],
Axolotl [42], Xenopus tropicalis [43,44], rat [45] and pig
[46]. Significantly, the CRISPR-Cas9 system has been
shown to be an efficient and reliable approach for tar-
geted modification of cynomolgus monkey genomes
[47]. The application of CRISPR-Cas9 technology for
genome editing in a wide range of organisms will pro-
mote our understanding of development and disease and
help develop animal models and therapeutic strategies
for human diseases.
CRISPR-Cas9 in somatic genome editing
Rapid progress in genome engineering based on the
CRISPR-Cas9 system enables fast functional characterization
of putative disease genes in various mouse models via
somatic genome editing [48-50]. A CRISPR plasmid
DNA expressing Cas9 and sgRNAs can be delivered to
the liver through hydrodynamic injection, and CRISPR-
mediated Pten mutation with or without p53 mutation
phenocopies the effects of PTEN and p53 gene knockout
using Cre-LoxP technology [48]. Previous studies have also
shown that an activated mutant β-catenin gene could be
delivered into hepatocytes by co-injection of Cas9 plasmids
expressing sgRNAs targeting the β-catenin gene and a
DNA oligonucleotide donor carrying β-catenin activating
point mutations [48]. This previous study demonstrated
that the CRISPR-Cas system could be used for directly mu-
tating tumor suppressor genes and oncogenes in somatic
tissues, providing a new approach for developing new types
of disease models. The CRISPR-Cas9 system has also been
used to induce a specific chromosomal rearrangement, the
Eml4-Alk inversion, in somatic cells of adult animals to
generate a mouse model of Eml4-Alk-driven lung cancer
[49]. The resulting tumors exhibit the typical histopatho-
logical and molecular features of ALK(+) human non-small
cell lung cancer (NSCLC), which is sensitive to ALK
inhibitors [49]. Interestingly, using a lentiviral-based
delivery system, a recent study demonstrated that
CRISPR-induced genome editing of tumor suppressor
genes together with Cre-dependent somatic activation
of oncogenic Kras(G12D) causes lung adenocarcin-
omas with different histopathological and molecular
features [50]. Using the Cas9 gene knockin mice, lung
adenocarcinoma models can be generated by simul-
taneously introducing a single AAV vector carrying
loss-of-function mutations in p53, Lkb1 and Kras(G12D)
mutations in the lung [38], suggesting that Cas9 geneknockin mice could be widely used for somatic genome
editing. The rapid somatic genome engineering approach
will greatly help to systematically identify critical genes
underlying disease initiation and progression in many
well-established disease mouse models.
CRISPR-Cas9 in functional genomic screening
Functional genomic screening is largely used for identi-
fying the essential genes for a specific cellular process.
RNA interference (RNAi) [51] has been dominantly ap-
plied for genome-wide screening; however, the off-target
effects of RNAi has limited its applications [52-54]. In
addition, RNAi could not be used for silencing RNAs lo-
cated in nucleus. The CRISPR-Cas9 system has been
successfully used in various genome-scale loss of func-
tion screening [55-58]. Using a genome-scale lentiviral
sgRNA library, all expected genes of the DNA mismatch
repair pathway have been identified in screening for
resistance to the nucleotide analog 6-thioguanine, and
numerous genes corresponding to fundamental processes
have been obtained with a negative selection screening for
essential genes [55]. A genome-scale CRISPR-Cas9 knock-
out (GeCKO) library has been developed and successfully
used for screening genes essential for cell viability in can-
cer and pluripotent stem cells and for genes associated
with the resistance to vemurafenib, a drug for late-stage
melanoma [56]. A CRISPR-Cas-based knockout library
has been applied to identify the host genes mediating the
cellular responses to anthrax and diphtheria toxins [57]. A
recent study has shown that saturation editing of genomic
regions could be achieved by coupling CRISPR-Cas9
technology with multiplex homology-directed repair
using a complex library of donor templates, facilitating
high-resolution functional screening of both cis-regulatory
elements and trans-acting factors in the genome [58].
A series of studies has demonstrated that CRISPR-
mediated repression (CRISPRi) and CRISPR-mediated
activation (CRISPRa) are powerful tools for functional
genomic screening. A CRISPRi system consisting of a
catalytically inactive Cas9 and a guide RNA has been
shown to specifically and efficiently repress the transcrip-
tion of target genes in Escherichia coli and mammalian
cells [59,60], whereas a catalytically inactive Cas9 fused
with a transcriptional activation domain has been used to
activate the expression of specific endogenous genes
[61-63]. Genome-scale CRISPRi and CRISPRa libraries
that specifically target transcriptional repressors or activa-
tors to endogenous genes have been successfully used for
screening essential genes for growth, tumor suppression,
differentiation regulation, and cellular sensitivity to a
cholera-diphtheria toxin, suggesting that CRISPRi and
CRISPRa are valuable tools for mapping complex path-
ways [64]. A very recent study has shown that CRISPR-
Cas9 complexes with synergistic activation mediators
Figure 2 Applications of CRISPR-Cas9 mediated genome engineering.
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upregulation at endogenous genomic loci. When used
with an sgRNA library, the engineered Cas9 activation
complexes can activate multiple genes simultaneously,
upregulate long intergenic non-coding RNA transcripts
and identify genes conferring resistance to a BRAF in-
hibitor through a genome-wide dCas9-based transcrip-
tion activation screening in a melanoma model [65].
These results demonstrate that CRISPR-Cas9 technology
can be a promising functional genomic screening tool for
discovering essential genes in various biological processes.
CRISPR-Cas9 in correction of genetic disorders
One of the most exciting applications of the CRISPR-Cas9
is the possibility of curing genetic diseases. The CRISPR-
Cas9 system has been shown to efficiently correct a domin-
ant Crygc gene mutation in a cataracts mouse model by
co-injecting Cas9 mRNA and sgRNA targeting the mutant
Crygc allele into zygotes [66]. A very recent study has
shown that the CRISPR-Cas9 system can be used to modify
an EGFP transgene or the endogenous Crygc gene in
spermatogonial stem cells (SSCs). The modified SSCs carry-
ing a corrected Crygc mutation can undergo spermatogen-
esis and produce offspring with the corrected phenotype at
an efficiency of 100% [67]. The injection of Cas9, sgRNA,
and homology-directed repair template into mouse zygotes
has been shown to correct the dystrophin gene mutation
responsible for muscular dystrophy in the germ line and
prevent the development of muscular dystrophy in mutant
mice [68]. Interestingly, a similar strategy using the
CRISPR-Cas9 technology has successfully corrected the
cystic fibrosis transmembrane conductor receptor (CFTR)
locus by homologous recombination in cultured intestinal
stem cells of cystic fibrosis human patients [69], demon-
strating that primary adult stem cells derived from patients
with a single-gene hereditary defect could be corrected by
CRISPR/Cas9 mediated homologous recombination,
suggesting a promising strategy for gene therapy in
human patients.
CRISPR-Cas9 in the treatment of infectious diseases
Considering that the CRISPR-Cas system originally func-
tions as an antiviral adaptive immune system in bacteria,
this system could be used for treating infectious diseases
by eradicating pathogen genomes from infected individ-
uals. Recently, studies have shown that the CRISPR-Cas9
system can eliminate the HIV-1 genome and prevent
new HIV infection [70,71]. When transfected into HIV-1
provirus-integrated human cells, an sgRNA expression
vector targeting the long terminal repeats (LTR) of HIV-
1 efficiently cleaves and mutates LTR target sites and
suppresses LTR-driven viral gene expression. In addition,
this system has been shown to delete viral genes from
the host cell chromosome [70]. The high specificity ofCas9/sgRNAs in editing the HIV-1 target genome has
also been recently demonstrated [71]. Cas9/sgRNAs effi-
ciently inactivate HIV gene expression and replication in
latently infected cells, including microglial, promonocytic
and T cells. Significantly, Cas9/sgRNA mediated genome
editing has been shown to immunize cells to prevent
HIV-1 infection [71]. These results indicate that the
CRISPR-Cas9 technology can serve as a potential tool
for clinical applications to cure infectious diseases.
Conclusions and perspectives
The CRISPR-Cas9 technology, an efficient, inexpensive,
fast-to-design, and easy-to-use genomic editing tool, has
been rapidly applied in many fields, ranging from basic
biology to translational medicine (Figure 2). The innovative
applications of the CRISPR-Cas9 system will accelerate our
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physiology and disease. The CRISPR-Cas9 technology will
also accelerate research related to military medical sciences.
Genome-wide functional screening will characterize essen-
tial genes that regulate host defense against pathogens. For
example, a CRISPR-Cas9 based screening identified the
host genes controlling the cellular responses to anthrax,
diphtheria toxins and cholera-diphtheria toxins, providing
new mechanisms of pathogen toxicity [53,55]. CRISPR-
Cas9-based rapid generation of targeted model organisms
will significantly boost the understanding of the mecha-
nisms of adaption to an extreme or specific environment. A
recent study using PAXX(-/-) cells generated by CRISPR-
Cas9 demonstrated that the PAXX gene plays a role in
DNA double-strand break repair and cell survival in re-
sponse to ionizing radiation [72]. In the immediate future,
the use of the CRISPR-Cas9 system will revolutionize mili-
tary medical sciences and advance the fundamental know-
ledge of anti-pathogen defense, radiation protection, tissue
homeostasis. Cas9/sgRNA mediated genome editing pro-
vides new therapeutic strategies for infectious diseases,
wound healing and tissue regeneration.
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